The 保健福利部 and the 中小企业部 announced a 'full-cycle collaboration plan to systematically support the growth and 全球拓展 of 制药 生物风投企业s.'
Package support will be provided from investment, 研发, and clinical entry to 全球拓展 to nurture venture candidates expected to create blockbuster drugs with annual sales exceeding $1 billion. At the policy discussion, a '4UP Strategy' focusing on scale-up, 开放式创新, ecosystem strengthening, and field collaboration was adopted.
Industry voices called for a 'virtuous cycle ecosystem between 生物风投企业s and 制药公司,' with key requests including addressing regional companies' limitations in attracting 风险资本, improving regulations for new modalities, and easing listing maintenance requirements. Strategic utilization to respond to the rapid growth of 中国's bio market was also discussed.
